ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Down 29.5% in April

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a large decline in short interest in April. As of April 15th, there was short interest totalling 113,800 shares, a decline of 29.5% from the March 31st total of 161,500 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 74,700 shares, the short-interest ratio is currently 1.5 days.

Analyst Ratings Changes

Separately, Morgan Stanley lifted their target price on shares of ABIVAX Société Anonyme from $15.00 to $16.00 and gave the company an “equal weight” rating in a research report on Thursday, April 11th.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Blackstone Inc. acquired a new position in ABIVAX Société Anonyme in the fourth quarter valued at about $25,345,000. Great Point Partners LLC acquired a new position in ABIVAX Société Anonyme in the fourth quarter valued at about $16,585,000. Commodore Capital LP acquired a new position in ABIVAX Société Anonyme in the fourth quarter valued at about $20,277,000. Ghisallo Capital Management LLC bought a new position in shares of ABIVAX Société Anonyme in the fourth quarter worth about $642,000. Finally, Capstone Investment Advisors LLC bought a new position in shares of ABIVAX Société Anonyme in the fourth quarter worth about $618,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Trading Up 0.3 %

Shares of ABIVAX Société Anonyme stock opened at $15.78 on Friday. ABIVAX Société Anonyme has a twelve month low of $7.99 and a twelve month high of $17.02. The company’s 50-day simple moving average is $14.44.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.